Biogen Launches Byooviz (biosimilar, ranibizumab) for the Treatment of Retinal Disorders in Canada
Shots:
- The company reported the commercial availability of Byooviz (ranibizumab injection), the first biosimilar referencing Lucentis for the treatment of serious eye disorders incl. neovascular (wet) AMD
- Additionally, the availability of Byooviz could enable more patients to access this type of vision-saving therapy as it brings a sustainable and cost-effective anti-VEGF treatment to Canadian vision care
- Byooviz was approved in Canada for the treatment of multiple eye disorders. The company's main goal is to advance the most diverse pipelines in neuroscience, which will revolutionize patient care in a no. of areas with a high unmet need
Ref: Newswire | Image: Biogen
Related News:- Biogen and Samsung Bioepis Launch Byooviz (biosimilar, ranibizumab) for the Treatment of Retinal Vascular Disorders in the US
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
